CLAIMS:

1. A neutralising antibody which binds human IL-17A and human IL-17F having a light chain wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:7.
2. A neutralising antibody according to claim 1 additionally comprising a heavy chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3.
3. A neutralising antibody according to claim 2, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:9.
4. An antibody according to any one of claims 1 to 3 which also binds the IL-17A/IL-17F heterodimer.
5. An antibody according to any one of claims 1 to 4, wherein the antibody is a whole antibody or functionally active fragment thereof.
6. The antibody according to claim 5 where the antibody fragment is selected from the group consisting of a Fab, Fab', $F(ab')_2$, scFv and Fv fragment.
7. An antibody according to any one of claims 1 to 4 wherein the antibody is a multi-specific antibody.
8. A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO:15 and a light chain comprising the sequence given in SEQ ID NO:11.
9. An isolated DNA sequence encoding the light chain of an antibody according to any one of claims 1 to 8.
10. An isolated DNA sequence encoding the heavy and the light chain of an antibody according to any one of claims 1 to 8.
11. A cloning or expression vector comprising the DNA sequence according to claim 9 or claim 10.
12. A vector according to claim 11, wherein the vector comprises the sequences given in SEQ ID NO:13 and SEQ ID NO:17.

13. A host cell comprising one or more cloning or expression vectors according to claim 11 or claim 12.

14. A process for the production of the antibody of any one of claims 1 to 8, comprising culturing the host cell of claim 13 and isolating the antibody.

15. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 8, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

16. A pharmaceutical composition according to claim 15, additionally comprising other active ingredients.

17. An antibody according to any one of claims 1 to 8 or a pharmaceutical composition according to claim 15 or 16, for use in therapy.

18. An antibody according to any one of claims 1 to 8 or a pharmaceutical composition according to claim 15 or claim 16, for use in the treatment or prophylaxis of a pathological condition selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associtated with infection, arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, chronic obstructive airways disease (COAD), chronic obstructive pulmonary disease (COPD), acute lung injury, pelvic inflammatory disease, Alzheimer's Disease, Crohn's disease, inflammatory bowel disease, irritable bwel syndrome, Ulcerative colitis, Castleman's disease, ankylosing spondylitis and other spondyloarthropathies, dermatomyositis, myocarditis, uveitis, exophthalmos, autoimmune thyroiditis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, atopic dermatitis, vasculitis, surgical adhesions, stroke, autoimmune diabetes, Type I Diabetes, lyme arthritis, meningoencephalitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis and Guillain-Barr syndrome, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, fibrosing disorders including pulmonary fibrosis, liver fibrosis, renal fibrosis, scleroderma or systemic sclerosis, cancer (both solid tumours such as melanomas, hepatoblastomas, sarcomas, squamous cell carcinomas, transitional cell cancers, ovarian cancers and hematologic malignancies and in particular acute myelogenous leukaemia, chronic myelogenous leukemia, chronic lymphatic leukemia, gastric cancer and colon cancer), heart disease including ischaemic

diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, periodontitis and hypochlorhydia.

19. The use of an antibody according to any one of claims 1 to 8 or a pharmaceutical composition according to claim 15 or claim 16 in the manufacture of a medicament for the treatment or prophylaxis of a pathological disorder that is mediated by IL-17A and/or IL-17F, or that is associated with an increased level of IL-17A and/or IL-17F.

CLAIMS

1. A neutralising antibody which binds human IL-17A and human IL-17F having a light chain and a heavy chain wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:7 and the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3.

2. A neutralising antibody according to claim 1, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:9.

3. An antibody according to claim 1 or claim 2 which also binds the IL-17A/IL-17F heterodimer.

4. An antibody according to any one of claims 1 to 3, wherein the antibody is a whole antibody or functionally active fragment thereof.

5. The antibody according to claim 4 where the antibody fragment is selected from the group consisting of a Fab, Fab', $F(ab')_2$, scFv and Fv fragment.

6. An antibody according to any one of claims 1 to 3 wherein the antibody is a multi-specific antibody.

7. A neutralising antibody which binds human IL-17A and human IL-17F, having a heavy chain comprising the sequence given in SEQ ID NO:15 and a light chain comprising the sequence given in SEQ ID NO:11.

8. An isolated DNA sequence encoding the light chain of an antibody according to any one of claims 1 to 7.

9. An isolated DNA sequence encoding the heavy and the light chain of an antibody according to any one of claims 1 to 7.

10. A cloning or expression vector comprising the DNA sequence according to claim 8 or claim 9.

11. A vector according to claim 10, wherein the vector comprises the sequences given in SEQ ID NO:13 and SEQ ID NO:17.

12. A host cell comprising one or more cloning or expression vectors according to claim 10 or claim 11.

13. A process for the production of the antibody of any one of claims 1 to 7, comprising culturing the host cell of claim 12 and isolating the antibody.

14. A pharmaceutical composition comprising an antibody according to any one of claims 1 to 7, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.

15. A pharmaceutical composition according to claim 14, additionally comprising other active ingredients.

16. An antibody according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 14 or 15, for use in therapy.

17. An antibody according to any one of claims 1 to 7 or a pharmaceutical composition according to claim 14 or claim 15, for use in the treatment or prophylaxis of a pathological condition selected from the group consisting of infections (viral, bacterial, fungal and parasitic), endotoxic shock associtated with infection, arthritis, rheumatoid arthritis, psoriatic arthritis, systemic onset juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), asthma, chronic obstructive airways disease (COAD), chronic obstructive pulmonary disease (COPD), acute lung injury, pelvic inflammatory disease, Alzheimer's Disease, Crohn's disease, inflammatory bowel disease, irritable bwel syndrome, Ulcerative colitis, Castleman's disease, ankylosing spondylitis and other spondyloarthropathies, dermatomyositis, myocarditis, uveitis, exophthalmos, autoimmune thyroiditis, Peyronie's Disease, coeliac disease, gallbladder disease, Pilonidal disease, peritonitis, psoriasis, atopic dermatitis, vasculitis, surgical adhesions, stroke, autoimmune

diabetes, Type I Diabetes, lyme arthritis, meningoencephalitis, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis and Guillain-Barr syndrome, other autoimmune disorders, pancreatitis, trauma (surgery), graft-versus-host disease, transplant rejection, fibrosing disorders including pulmonary fibrosis, liver fibrosis, renal fibrosis, scleroderma or systemic sclerosis, cancer (both solid tumours such as melanomas, hepatoblastomas, sarcomas, squamous cell carcinomas, transitional cell cancers, ovarian cancers and hematologic malignancies and in particular acute myelogenous leukaemia, chronic myelogenous leukemia, chronic lymphatic leukemia, gastric cancer and colon cancer), heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, intravascular coagulation, bone resorption, osteoporosis, periodontitis and hypochlorhydia.